Benefits and limitations of whole genome versus targeted approaches for noninvasive prenatal testing for fetal aneuploidies. (17th May 2013)

• Record Type: Journal Article
• Authors: Boon, Elles M. J.; Faas, Brigitte H. W.; Chitty, Lyn S.; Bianchi, Diana W.
• Is Part Of: Prenatal diagnosis. Volume 33:Number 6(2013:Jun.)
• Page Start: 563
• Page End: 568
• Publication Date: 2013-05-17
• Subjects: Prenatal diagnosis -- Periodicals; Fetus -- Diseases -- Diagnosis -- Periodicals; Electronic journals; 618.32075
• DOI: 10.1002/pd.4111
• Languages: English
• ISSNs: 0197-3851

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>The goal to noninvasively detect fetal aneuploidies using circulating cell‐free fetal DNA in the maternal plasma seems to be achieved by the use of massively parallel sequencing (MPS). To date, different MPS approaches exist, all aiming to deliver reliable results in a cost effective manner. The most widely used approach is the whole genome MPS method, in which sequencing is performed on maternal plasma to determine the presence of a fetal trisomy. To reduce costs targeted approaches, only analyzing loci from the chromosome(s) of interest has been developed. This review summarizes the different MPS approaches, their benefits and limitations and discusses the implications for future noninvasive prenatal testing. © 2013 John Wiley &amp; Sons, Ltd.</p> </abstract>